ImmuPharma plc (LON:IMM – Get Free Report) dropped 10.1% during mid-day trading on Thursday . The stock traded as low as GBX 3.75 and last traded at GBX 4. 785,293 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 2,605,068 shares. The stock had previously closed at GBX 4.45.
ImmuPharma Trading Down 10.1%
The firm’s fifty day moving average price is GBX 4.16 and its 200-day moving average price is GBX 5.19. The company has a market cap of £24.96 million, a P/E ratio of -10.81 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last released its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. As a group, research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
- Astera Labs’ Post-Earnings Pullback May Be Last Chance to Buy Below $360
- McDonald’s Stock Sell-Off: Justified Warning or Buying Opportunity?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
